Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 00973

Next Previous
X
Search
Drug Profile

TT 00973

Alternative Names: TT-00973; TT-00973-MS

Latest Information Update: 03 Feb 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransThera Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 12 Jan 2023 Preclinical trials in Acute myeloid leukaemia in China (PO) before January 2023 (TransThera Biosciences pipeline, January 2023)
  • 12 Jan 2023 Preclinical trials in Solid tumours in China (PO) before January 2023 (TransThera Biosciences pipeline, January 2023)
  • 10 Jan 2023 TransThera Biosciences plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater)in China (PO, Tablet) (NCT05673538)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top